Eris Lifesciences Partners with Natco Pharma for Semaglutide Launch in India

Eris Lifesciences, a leading Indian branded formulations company, has announced a strategic partnership with Natco Pharma Limited for the commercialisation of Semaglutide in India. Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management. Eris has built a strong presence in diabetology and the addition of semaglutide is expected to further strengthen its portfolio in advanced diabetes therapies. The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape. The launch is expected in March 2026, subject to regulatory approvals and other factors.